Akeros lead candidate, EFX , targets MASH (metabolic-associated steatohepatitis) and is the only therapy to show meaningful regression in liver damage from cirrhosis
It modulates neutrophil and macrophage activity to dampen tissue-damaging inflammation and promotes clearance of infection
However, the precise molecular mechanisms underlying these alterations, particularly the relationship between GSSG reduction and the acute exacerbation of psychotic symptoms, require further investigation
Fortunately, a better quality of life is just a phone call to A New You away!
Although technically two copies of both genes (homozygous) would be worse, it is very uncommon, whereas the heterozygous C677T/1298C is much more commonly the worst case scenario I have double gene mutation homozygous hereditary hemochromatosis I have SEVERE CFS SEVERE FIBRO DEPRESSION ANXIETY BIPOLAR SEVERE MCS